diff --git a/Latex/Paper/sections/05_LitReview.tex b/Latex/Paper/sections/05_LitReview.tex
index e3177e1..97ea175 100644
--- a/Latex/Paper/sections/05_LitReview.tex
+++ b/Latex/Paper/sections/05_LitReview.tex
@@ -104,6 +104,10 @@ They find that when Medicare part D was implemented -- increasing senior
 citizens' ability to pay for drugs -- there was a (delayed) increase 
 in drug development, with effects concentrated among compounds that were least
 innovative according to their classification of innovations.
+They suggest that this is due to financial risk management, as novel 
+pharmaceuticals have a higher probability of failure compared to the less novel
+follow up development. 
+This is what leads risk-adverse companies to prefer follow up development.
 
 
 % Acemoglu and Linn
@@ -124,12 +128,25 @@ Among non-generics, a 1\% increase in potential market size
 \cite{gupta_OneProduct_2020} discovered that uncertainty around which patents
 might apply to a novel drug causes a delay in the entry of generics after 
 the primary patent has expired. 
-She found that this delay averages around 3 years. 
+She found that this delay in delivery is around 3 years. 
 
 % Agarwal and Gaule 2022
 % - Retrospective on impact from COVID-19 pandemic
 % Not in this version
 
 %DiMasi FeldmanSeckler Wilson 2009
+\cite{dimasi_TrendsRisks_2010} examine the completion rate of clinical drug 
+develompent and find that for the 50 largest drug producers, 
+approximately X\% of their drugs under developm
+successfully completed the process. 
+They note a couple of changes in how drugs are developed over the years they 
+study (clinical development started between 1993 and 2004). 
+This included that drugs began to fail earlier in their development cycle in the 
+latter half of the time they studied. 
+This may be an operational change to reduce the cost of new drugs. 
+
+\cite{dimasi_ValueImproving_2002}
+used data on 68 investigational drugs from 10 firms to simulate how reducing
+time in development adds to the 
 
 \end{document}